title: Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal.
abstract: Two applications each claim compounds described as selective PI3Kδ inhibitors. The first claims 2-amino-3-substituted-8-methylquinoline derivatives. The second, more substantial, application claims a broad range of cyclic amine derivatives of 6-aminopurines. These are the first patent applications from Exelixis relating to its PI3Kδ inhibitor program despite its disclosure of the biological profile of its lead inhibitor XL-499 in late 2010.
authors: Norman Consulting, 18 Pink Lane, Burnham, Bucks SL1 8JW, UK. peter.norman2@btinternet.com
authors: Peter
authors: P
authors: Norman
mesh_terms: D000818:Animals; D016527:Drug Costs / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence; D006801:Humans; D007880:Legislation, Drug / Q000191:economics; D015394:Molecular Structure; D010330:Patents as Topic; D058539:Phosphatidylinositol 3-Kinase / Q000737:chemistry / Q000191:economics / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011487:Protein Conformation; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000191:economics / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D014481:United States
chemical_list: D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D058539:Phosphatidylinositol 3-Kinase